Company profile
ANI PHARMACEUTICALS INC
NASDAQ:ANIPBiotechnology: Pharmaceutical Preparations
Drug pipeline (159)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ACEBUTOLOL HYDROCHLORIDE | approved | — | 0 | — |
| ACETAMINOPHEN AND CODEINE PHOSPHATE | approved | — | 78 | approved |
| ACETOHEXAMIDE | approved | — | 0 | — |
| ALPRAZOLAM | approved | — | 7 | approved |
| AMINOCAPROIC ACID | approved | — | 0 | — |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (0)
No records yet.
FDA applications (251)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| ANDA 214844 | 2025-02-03 | ANDA | ANI PHARMACEUTICALS INC | |||||
Loading… | ||||||||
| ANDA 215901 | 2024-01-25 | ANDA | ANI PHARMACEUTICALS INC | |||||
Loading… | ||||||||
| ANDA 208237 | 2023-12-15 | ANDA | ANI PHARMACEUTICALS INC | |||||
Loading… | ||||||||
| ANDA 217252 | 2023-06-08 | ANDA | ANI PHARMACEUTICALS INC | |||||
Loading… | ||||||||
| ANDA 216517 | 2023-03-10 | ANDA | ANI PHARMACEUTICALS INC | |||||
Loading… | ||||||||